NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP): Evaluating Valuation After Casgevy Sales Surge and Pipeline Innovation
CRISPR Therapeutics (CRSP) just gave investors plenty to talk about. Shares have surged in recent months, fueled by a powerful combination of positive trial news from the in-vivo candidate CTX310 and a dramatic 114% jump in Q2 Casgevy sales. With Casgevy now approved for both sickle cell disease and transfusion-dependent beta-thalassemia, these latest updates are clear signals that market adoption is gaining real traction. The product pipeline is also expanding in unexpected new directions,...